Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Immunic is a clinical-stage biotechnology company developing selective oral immunology therapies targeting chronic inflammatory and autoimmune diseases. The company's lead asset vidofludimus calcium (IMU-838) is in Phase 3 trials for relapsing-remitting multiple sclerosis (CALLIPER study) and progressive MS (ENSURE studies), with additional programs including IMU-856 for gastrointestinal diseases and IMU-381 for cancer. With no revenue and $100M annual cash burn, the stock trades on clinical trial readouts, regulatory milestones, and financing risk.
Immunic operates a classic biotech development model: advance proprietary compounds through clinical trials, obtain regulatory approval, then either commercialize directly in select markets or partner with larger pharmaceutical companies for royalty-based revenue. Vidofludimus calcium targets the DHODH enzyme pathway with differentiation from existing MS therapies through oral administration and potentially superior safety profile versus injectable biologics. Monetization depends entirely on successful Phase 3 trial completion (CALLIPER primary endpoint expected 2026-2027), FDA/EMA approval, and either partnership deals with big pharma or direct commercialization requiring significant capital raise. IMU-856 represents optionality in inflammatory bowel disease with Phase 2 data generation ongoing. The company has no pricing power until regulatory approval and faces binary risk on each clinical readout.
CALLIPER Phase 3 trial interim analyses and primary endpoint readout for vidofludimus calcium in relapsing-remitting MS (expected 2026-2027 based on enrollment timelines)
ENSURE Phase 3 trial enrollment progress and data readouts for progressive MS indication
IMU-856 Phase 2 data in ulcerative colitis showing efficacy on endoscopic endpoints and safety profile versus existing JAK inhibitors
Partnership announcements or licensing deals with major pharmaceutical companies for ex-US rights or specific indications
Equity financing announcements (dilution risk given negative operating cash flow and limited runway)
FDA/EMA regulatory feedback on trial designs or breakthrough therapy designation applications
Binary clinical trial risk - Phase 3 failure of vidofludimus calcium would eliminate 70%+ of company value given pipeline concentration; MS trials require multi-year follow-up with high statistical bars for superiority or non-inferiority versus established therapies like Tecfidera, Ocrevus
Regulatory approval uncertainty - FDA/EMA may require additional safety studies, larger patient populations, or longer follow-up periods even with positive efficacy data; competitive MS landscape with 20+ approved therapies raises bar for differentiation
Financing risk and dilution - current $100M cash position insufficient to reach commercialization; likely requires $200-300M additional capital through 2028, resulting in substantial shareholder dilution at depressed valuations if trials show mixed results
Crowded MS therapeutic landscape with entrenched competitors (Biogen, Novartis, Roche, Bristol Myers Squibb) offering proven efficacy; vidofludimus calcium must demonstrate superior safety/tolerability or efficacy to gain formulary access and reimbursement
Oral MS therapies face competition from Tecfidera (dimethyl fumarate), Mayzent, Zeposia with established safety databases; newer BTK inhibitors from Merck and Sanofi in late-stage development may preempt market opportunity
IBD program (IMU-856) competes against established biologics (Humira, Stelara, Entyvio) and newer oral agents (Rinvoq, Zeposia) with significant head start in market penetration
Liquidity crisis risk - 12-18 month cash runway at current burn rate requires near-term financing; equity raises at current $100M market cap would be highly dilutive (50%+ dilution likely for $50M raise)
Negative working capital dynamics - current ratio of 1.31 indicates limited buffer; accounts payable to CROs and manufacturing partners create lumpy cash outflows tied to trial milestones
Going concern risk if CALLIPER trial shows futility at interim analysis - would trigger strategic review, potential asset sales, or wind-down scenario
low - Clinical-stage biotechs are largely insulated from GDP fluctuations as R&D spending is committed regardless of economic conditions. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) partnership deal terms as pharma companies become more conservative, (3) patient enrollment in trials if economic stress affects healthcare access. MS and IBD patient populations are relatively stable through cycles as these are chronic conditions requiring continuous treatment.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (vidofludimus calcium revenue unlikely before 2028-2029 even in best case). Higher rates also increase opportunity cost of holding cash-burning pre-revenue assets versus fixed income alternatives, compressing biotech multiples. Financing costs rise for future capital raises though Immunic's minimal debt (0.01 D/E) limits direct interest expense impact. Rate environment critically affects IPO/follow-on offering windows and SPAC merger alternatives for funding.
Minimal direct credit exposure as company has negligible debt and operates on equity financing model. However, credit market conditions indirectly affect ability to raise capital - widening high-yield spreads and credit stress reduce investor appetite for speculative biotech equity. Tighter credit also impacts potential pharma partners' M&A capacity and willingness to pay upfront milestone payments in licensing deals.
growth/speculative - Attracts biotech-specialized investors, venture capital crossover funds, and retail traders seeking asymmetric risk/reward on binary clinical catalysts. Not suitable for value or income investors given negative earnings, no dividends, and high probability of total loss if trials fail. Typical holder profile includes healthcare-focused hedge funds with diversified biotech portfolios to manage binary risk, and momentum traders around data readout catalysts. Institutional ownership likely concentrated among specialist healthcare funds rather than broad index investors.
high - Small-cap clinical-stage biotechs exhibit extreme volatility with 50-80% single-day moves common on trial data releases. Stock beta likely 1.5-2.0x versus broader market given $100M market cap, limited liquidity, and binary event risk. Three-month return of +25.7% followed by one-year return of -15.8% illustrates typical boom-bust pattern around hope/disappointment cycles. Options market likely prices 80-100% implied volatility around known data catalysts.
